Alzheimer Disease Clinical Trial
— DTADOfficial title:
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Verified date | July 2023 |
Source | Boston University |
Contact | Wendy Qiu, MD PhD |
Phone | (617) 358-1886 |
wqiu67[@]bu.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this multi-center study, the investigators plan to develop a simple blood-based test for early detection of Alzheimer's disease (AD). The test is based on a single injection of Pramlintide, an amylin analogue and FDA-approved drug currently used for treatment of diabetes. The investigative team has provided evidence in humans with full-blown AD and AD-relevant mouse models that a single injection of Pramlintide transiently renders the blood brain barrier (BBB) more permeable to Amyloidbeta (Aß) peptides, allowing their efflux from the brain compartment into the blood. This Aß efflux causes a corresponding transient elevation of blood levels of Aß, the magnitude of which the applicants believe is proportional to the brain amyloid load as determined by AV-45 PET. The measured difference in the level of plasma Aß taken just before and a short time after injection should reveal the magnitude of the transient increase in blood Aß levels. Supportive preliminary data comes from later stage (full-blown) AD patients with more in-depth background studies in Tg2576 and 5X Familial Alzheimer's Disease (FAD) mouse models. If successful for use as an early AD (i.e., at the Mild Cognitive Impairment [MCI] stage) biomarker, this could be a game-changer for both early AD diagnostics and clinical trials aimed at identifying and testing the efficacy of drugs useful for treatment of AD at early stages. If Pramlintide is effective in releasing mobile pools of Aß from the brain into the blood, this could also have some therapeutic potential, with the goal of reducing brain amyloid load. Three groups of particpants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | November 2026 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 90 Years |
Eligibility | Inclusion Criteria: - Current research subjects at the BU ADC, VA BHS, or IU ADC - A consensus diagnosis of probable AD, amnestic MCI, or control - BMI of 20-35 - Probable AD subjects must be confirmed for positive AD pathology in the CNS - Probable AD subjects must have a designated research proxy signed before they became demented. Exclusion Criteria: - Diabetes mellitus - Gastroparesis - Use of insulin, pramlintide, other injectable anti-hyperglycemic agents, such as glucagon like peptide-1 (GLP-1), or oral anti-diabetic products - Unexplained hypoglycemia (glucose = 60 mg/dL) or hyperglycemia (glucose = 126 mg/dL) pre-injection - History of stroke - Seizures or use of anti-seizure medications - History of brain injury and loss of consciousness - Diagnosed cerebral amyloid angiopathy (CAA) - Infection within 1 month |
Country | Name | City | State |
---|---|---|---|
United States | BU Alzheimer Disease Center | Boston | Massachusetts |
United States | Indiana University Alzheimer Disease Center | Indianapolis | Indiana |
United States | Memory Center VA Boston Healthcare | Jamaica Plain | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston University | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma Aß and t-tau changes | Plasma Aß1-40 and Aß1-42 data will be analyzed. For each peptide, the mean ± SD, median, 25%, 75%, and range | 5, 30, 60, and 180 min after challenge test | |
Primary | Plasma inflammatory changes | Changes in proinflammatory-related biomarkers: particularly the IL-1ß/IL-1Ra pathway, as well as GM-CSF, G-CSF, Trem2, CD36, and CD163, CD68 will be measured applying high-density multiplex ELISA assays (RayBiotech, Norcross, GA) | 5, 30, 60, and 180 min after challenge test | |
Primary | Plasma metabolic changes in blood | Changes in 2. Metabolism biomarkers associated with amylin: leptin, GLP-1, RBP4, Insulin R, ApoE, and ApoJwill be measured applying high-density multiplex ELISA assays (RayBiotech, Norcross, GA) | 5, 30, 60, and 180 min after a pramlintide challenge test | |
Secondary | Change in MMSE | MMSE range is from 1-30, we expect a positive challenge test will have a decrease of MMSE | baseline, 12 and 24 months post challenge | |
Secondary | Change in CDR | CDR range is from 0-3, we expect a positive challenge test for increased CDR score | baseline, 12 and 24 months post challenge | |
Secondary | Change in NAB | We expect NAB to be decreased | baseline, 12 and 24 months post challenge | |
Secondary | Change in WMS-III Logical Memory | WMS-III range is from 0-25, we expect a decrease in WMS-III Logical memory | baseline, 12 and 24 months post challenge | |
Secondary | Change in CLOX paradigm | CLOX paradigm range is from 0-3, we expect a decrease in this paradigm | baseline, 12 and 24 months post challenge | |
Secondary | Change in Trailmaking Test Part B | Trailmaking Test Part B range is from 0-300 seconds, we expect an increase in this test | baseline, 12 and 24 months post challenge | |
Secondary | Change in Controlled Oral Word Association Test | Controlled Oral Word Association Test has no range, we expect this to be decreased | baseline, 12 and 24 months post challenge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |